The College of Pharmacy, Center of Drug Evaluation & Safety, in partnership with the Center for Pharmacogenomics and Precision Medicine, would like to welcome Stephen E. Kimmel, MD, MSCE, FAHA, FISPE, FACE as our invited guest speaker. He will present his talk, entitled: “Precision Medicine Meets Precision Methods.”
Please join us this Tuesday, 11/19/2019 from 9:00am to 10:00am in Communicore C1-17.
Title: “Precision Medicine Meets Precision Methods”
Stephen Kimmel, MD, MSCE, FAHA, FACC, FISPE, FACE, is Professor of Epidemiology and Medicine at the University of Pennsylvania Perelman School of Medicine; Director of the Division of Epidemiology in the Department of Biostatistics, Epidemiology and Informatics (DBEI); and Director of the Epidemiology Unit within the Center for Clinical Epidemiology and Biostatistics (CCEB). He is also the founding director of the Center for Therapeutic Effectiveness Research (CTER) at Penn. Dr. Kimmel oversees all activities within the Division of Epidemiology, including the support of 60 faculty members, a Master of Science in Clinical Epidemiology program, and a Ph.D. in Epidemiology. His own work focuses on improving the use of existing therapies through the performance of clinical studies of medications and randomized trials of interventions to improve medical treatments. His work includes large-scale population studies, such as a more-than-8,500 person study examining the effects of non-steroidal anti-inflammatory drugs and COX-2 inhibitors on myocardial infarction; and a multi-center prospective cohort of genetic and adherence determinants of warfarin response. He was a principal investigator on a multicenter clinical trial, funded by the Pennsylvania Department of Health and industry support, that was designed to improve adherence and thus blood pressure control with antihypertensive medications. He has served as principal investigator on an R01-funded multicenter trial of lottery incentives and reminder systems for warfarin treated patients. He was also the principal investigator for the Clinical Trial Coordinating Center of a large, National Heart, Lung and Blood Institute-sponsored, multicenter clinical trial of pharmacogenetic-based dosing of warfarin, the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. His current work includes patient-centered outcomes research in heart failure, novel methods for prediction modeling, and innovative methods of improving adherence.